SoniVie Ltd. announced today the appointment of Raymond W Cohen to serve as its chairman of the board of directors.
Cohen has served as the chief executive officer (CEO) and member of the board of directors of Axonics, a global medical technology company he co-founded in 2013 and took public 31 October 2018. Axonics ranked number 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the fastest growing companies in the Americas.
Cohen is retiring from Axonics following the close of its US$3.7 billion sale to Boston Scientific Corporation.
Prior to Axonics, Cohen was the CEO of Vessix Vascular, which developed a catheter based renal denervation system that was acquired by Boston Scientific in late 2012.
Tomaso Zambelli, CEO of SoniVie, said “We look forward to benefiting from Cohen’s broad experience in growing Medtech companies and moreover his expertise in renal denervation as we execute our PMA [prospective meta-analysis] study for US FDA [Food and Drug Administration] approval and make plans to commercialise our product.”
An accredited public company director with over 40 years of experience in the life sciences industry, Cohen also serves as an independent director of Kestra Medical Technologies, a commercial stage company manufacturing and marketing a wearable defibrillator product for patients at temporary risk of cardiac arrest.
Cohen recently received the 2024 MedTech MVP Award, and was also named Businessperson of the Year by the Orange County Business Journal. In 2021, Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In late 2020, Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest USA.
